Technology
Health
Pharmaceutical
Akari Therapeutics
$2.769876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.76
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.18 (-6.12%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell AKTX and other stocks, options, ETFs, and crypto commission-free!
About
Akari Therapeutics Plc ADR, also called Akari Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. Read More The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
Employees
14
Headquarters
London, London & South East
Founded
2004
Market Cap
43.63M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
658.01K
High Today
$2.97
Low Today
$2.75
Open Price
$2.95
Volume
59.02K
52 Week High
$9.20
52 Week Low
$1.56
Collections
Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2015 IPO
UK
News
Yahoo FinanceApr 23
Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights
Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid (BP) resulted in no drug-related adverse events and rapid reduction in BP Disease Area Index (BPDAI) score and blistering in ongoing Phase II clinical trial Pivotal clinical trial for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) expected to start Q4 2019 Initial data on atopic keratoconjunctivitis (AKC) and pre-clinical back of the eye program to be presented at As...
Price Paid on Robinhood
46% Lower
Right Now
52 Week Low
$1.56
Average Price Paid
$5.11
52 Week High
$9.20
Earnings
-$0.66
-$0.44
-$0.22
$0.00
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Sep 26, Pre-Market